Vanda Pharmaceuticals Inc.
VNDA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VNDA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system, gastrointestinal, and rare disease indications, with a pipeline spanning multiple clinical-stage programs and recent commercial launches.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$319.8M
Cash Runway
11.5 moLead Asset
bysanti (Approved)
Next Catalyst
Phase3_Topline · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 29 clinical trials · 14 catalysts · 6 FDA decisions for Vanda Pharmaceuticals Inc..
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system, gastrointestinal, and rare disease indications, with a pipeline spanning multiple clinical-stage programs and recent commercial launches.
- Cash and equivalents of $56.4M as of 2026-06-30 [sec].
- Total revenue of $50.5M for the six months ended 2026-06-30 [sec].
- Net loss of $62.5M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $486.3M as of 2026-06-30 [sec].
- NEREUS (tradipitant) commercially launched in the U.S. in May 2026 for prevention of vomiting induced by motion [sec_mda · as of 2026-08-06].
What works
- Multiple approved commercial products generating revenue, including Fanapt, HETLIOZ, PONVORY, and NEREUS [sec_mda · as of 2026-08-06].
- Deep pipeline with several Phase 3 trials ongoing for tasimelteon, tradipitant, and other candidates across various indications [sec_mda · as of 2026-08-06].
- Strong balance sheet with $486.3M in shareholders' equity and low debt of $3.2M as of 2026-06-30 [sec].
- Upcoming catalysts include multiple Phase 3 topline readouts through 2028, providing potential value inflection points [upcoming catalysts].
What to weigh
- Net loss of $62.5M for the six months ended 2026-06-30 indicates ongoing operating losses [sec].
- Significant reliance on successful clinical development and regulatory approval for pipeline products, with no assurance of outcomes [sec · filed 2026-08-05].
- Remaining milestone obligations of $44.9M for development, regulatory, and sales milestones as of March 31, 2026 [sec_mda · as of 2026-05-07].
- Commercial launches of NEREUS and upcoming BYSANTI carry execution risk and require market adoption [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
NEREUS commercially launched in the U.S. in May 2026
“the ongoing commercial launch of NEREUS TM for the prevention of vomiting induced by motion, which became commercially available in the United States (U.S.) in May 2026”
SEC MD&A · August 6, 2026
Remaining milestone obligations of $44.9M as of March 31, 2026
“remaining milestone obligations include $ 11.9 million for development milestones and $ 33.0 million for future regulatory approval and sales milestones”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2026-09-01 · Phase 3 Topline: Tasimelteon vs. Placebo (indication not specified) — First of several Phase 3 readouts for tasimelteon; results will inform efficacy and safety in the studied population.
- 2026-12-01 · Phase 3 Topline: Thetis Study (tradipitant) — Thetis study evaluates tradipitant; topline data will be a key catalyst for the motion sickness program.
- 2026-12-31 · Phase 2 Topline: Nereus (tradipitant) — Phase 2 readout for tradipitant in an additional indication; results may support further development.
- 2027-04-01 · Phase 3 Topline: Tasimelteon (another study) — Additional Phase 3 data for tasimelteon; multiple readouts increase the probability of at least one positive outcome.
- 2027-11-01 · Phase 3 Topline: Study in Schizophrenia (iloperidone LAI?) — Withdrawal study in schizophrenia patients; results will inform long-acting injectable strategy.
- 2027-12-30 · Phase 3 Topline: Motion Delos (tradipitant) — Open-label safety/efficacy study of tradipitant; supports regulatory filing for motion sickness.
- 2028-01-01 · Phase 3 Topline: Tasimelteon (another study) — Further Phase 3 data for tasimelteon; broad pipeline of indications under investigation.
- 2028-03-01 · Phase 3 Topline: Another study (ponsimod?) — Additional Phase 3 readout; expands pipeline optionality.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Pipeline products may fail in clinical trials, leading to write-offs and no return on investment [sec · filed 2026-08-05].
- Regulatory approval uncertainty — Even if trials succeed, FDA or other regulators may not approve new drugs or indications [sec · filed 2026-08-05].
- Commercial launch execution — New product launches (NEREUS, BYSANTI) may underperform due to competition, pricing, or market access issues [sec_mda · as of 2026-08-06].
- Financial sustainability — Ongoing net losses and milestone obligations may pressure cash reserves if revenue growth stalls [sec].
What to watch
- Phase 3 topline results for tasimelteon in various indications expected from September 2026 through 2028 [upcoming catalysts].
- Commercial uptake of NEREUS following its May 2026 U.S. launch [sec_mda · as of 2026-08-06].
- Regulatory decisions and launch progress for BYSANTI in bipolar disorder and schizophrenia [sec_mda · as of 2026-08-06].
- Financial performance in upcoming quarters, particularly revenue trends and cash burn rate [sec].
Sources: News · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Vanda Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vanda Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
11.5 months
D/E 0.87 · 0% dilution
Lead: Approved
5 candidates
14 upcoming, next in ~2d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 10.8%
- Days to cover
- 5.7
- Shares short
- 6,196,446
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VNDA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vanda Pharmaceuticals Inc.?
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system, gastrointestinal, and rare disease indications, with a pipeline spanning multiple clinical-stage programs and recent commercial launches.
What is Vanda Pharmaceuticals Inc.'s lead drug candidate?
Vanda Pharmaceuticals Inc.'s most advanced tracked candidate is bysanti (Approved).
What is Vanda Pharmaceuticals Inc.'s next catalyst?
Vanda Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in " — expected September 1, 2026.
Who is the CEO of Vanda Pharmaceuticals Inc.?
Dr. Mihael H. Polymeropoulos M.D. is the chief executive officer of Vanda Pharmaceuticals Inc. (VNDA).
Where is Vanda Pharmaceuticals Inc. headquartered?
Vanda Pharmaceuticals Inc. (VNDA) is headquartered in Washington, DC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.